Biosimilar

Satumomab Biosimilar Pipeline Development Service

Comprehensive Solutions for TAG-72-Targeted Biosimilar Development

Creative Biolabs delivers comprehensive Satumomab biosimilar development support, guiding projects from initial analytical assessments through to regulatory filings. Our team brings extensive experience in antibody engineering and TAG-72 targeting technology, enabling accelerated development timelines without compromising scientific rigor or compliance. We employ advanced characterization methods and robust process optimization to ensure biosimilarity while meeting stringent regulatory requirements. Our end-to-end approach minimizes risks and maximizes efficiency throughout the development lifecycle, helping clients bring high-quality biosimilars to market faster.

At a glance of Satumomab

Service Overview

Satumomab is a murine monoclonal antibody that binds with high specificity to TAG-72, a tumor-associated glycoprotein overexpressed in adenocarcinomas such as colorectal, ovarian, and pancreatic cancers. Originally developed for radioimmunoscintigraphy in cancer diagnostics, its ability to precisely localize tumors has made it a valuable tool in oncology imaging, though its murine origin limits therapeutic applications due to potential immunogenicity and human anti-mouse antibody (HAMA) responses. Despite these limitations, Satumomab serves as an important reference in antibody engineering, particularly in the development of biosimilars and improved targeting strategies, as researchers explore humanized variants and enhanced delivery systems to overcome immunogenicity while maintaining its high tumor-targeting affinity. Its well-characterized binding properties continue to inform advancements in cancer diagnostics and targeted therapies, reinforcing its role in the evolution of precision oncology even as newer technologies emerge.

Basic Information

Drug Type: Monoclonal antibody

Target: TAG-72

Action: Inhibitors

Mechanism: Tumor-associated glycoprotein 72 inhibitors

Originator Organization: CytoGen, Inc.

Pipeline Status

Our Satumomab Biosimilar Pipeline Offers

Fig.1 Satumomab Biosimilar Pipeline. (Creative Biolabs Original)

Development Workflow of Satumomab Biosimilar Pipeline

Early Development & Analytical Characterization
1	Target Molecule Characterization & Reference Product (RLD) Analysis	Reference Product Selection: Identify the originator biologic. Comprehensive Characterization: Primary Structure: Amino acid sequencing, post-translational modifications (glycosylation, deamidation). Higher-Order Structure: X-ray crystallography, NMR, or cryo-EM for 3D conformation. Functional Assays: Binding affinity (SPR/BLI), Fc effector functions (ADCC/CDC), and biological activity (cell-based assays).
2	Cell Line Development & Upstream Process	CHO (Chinese Hamster Ovary) or other mammalian cells optimized for mAb production. Cloning of the Satumomab heavy/light chain genes with optimized promoters. High-throughput screening for high-titer, stable clones (e.g., using FACS or automated systems).
3	Downstream Purification Process	Harvest & Clarification: Depth filtration, centrifugation. Viral Clearance: Low-pH inactivation, nanofiltration. Ultrafiltration/Diafiltration (UF/DF): Formulation buffer exchange.
Non-Clinical Development
4	In Vitro Characterization	Binding Affinity & Specificity. Fc Functionality. Potency Assays.
5	In Vivo Studies	Dose-response studies in relevant animal models. Biomarker analysis. Immunogenicity assessment.

Available Packages

Creative Biolabs delivers modular and scalable services for Satumomab biosimilar development. Whether you require targeted comparability studies or comprehensive regulatory preparation, our flexible offerings adapt to your needs. Let us tailor a solution for your specific goals.

NO.	Item Name	Includes	Deliverables
1	Early-Stage Analytical Characterization	Recombinant expression of TheraMab biosimilar Purity/identity analysis (HPLC-MS, icIEF) Target binding kinetics (BLI, ELISA) Fc effector function assays (ADCC, CDC) Accelerated stability studies	Analytical comparability report Raw datasets & CoA Glycosylation profile
2	For preclinical proof-of-concept and IND-enabling studies	In vitro potency assays (e.g., tumor cell inhibition) Rodent/non-human primate PK/PD studies High-titer stable cell line development (CHO) Upstream/downstream process optimization	Preclinical study reports Cell line characterization data Process validation documents

Why Choose Us

Comprehensive & Phase-Specific Expertise

Early-Stage Development.
Preclinical & IND-Enabling Studies.
End-to-End Support.

Risk Mitigation & Efficiency

Reduced timelines with integrated workflows.
Forced degradation & stability studies to de-risk formulation.
Regulatory-aligned approaches (though we do not provide final submission dossiers).

Flexible Collaboration Models

Choose modular service packages (e.g., standalone analytics or full development).
Custom solutions for unique challenges (e.g., complex glycosylation profiles).

Ready to Advance Your Satumomab Biosimilar Program

Contact us to craft a bespoke development strategy aligned with your regulatory requirements and timeline. Request a quote, arrange a technical discussion, or access our detailed service portfolio today.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.